Εμφάνιση απλής εγγραφής

dc.creatorCuadrado I., Saura M., Castejón B., Martin A.M., Herruzo I., Balatsos N., Zamorano J.L., Zaragoza C.en
dc.date.accessioned2023-01-31T07:48:30Z
dc.date.available2023-01-31T07:48:30Z
dc.date.issued2016
dc.identifier10.1017/erm.2016.5
dc.identifier.issn14623994
dc.identifier.urihttp://hdl.handle.net/11615/72970
dc.description.abstractCardiovascular diseases are the leading cause of death in developed countries. The aetiology is currently multifactorial, thus making them very difficult to prevent. Preclinical models of atherothrombotic diseases, including vulnerable plaque-associated complications, are now providing significant insights into pathologies like atherosclerosis, and in combination with the most recent advances in new non-invasive imaging technologies, they have become essential tools to evaluate new therapeutic strategies, with which can forecast and prevent plaque rupture. Positron emission tomography (PET)/computed tomography imaging is currently used for plaque visualisation in clinical and pre-clinical cardiovascular research, albeit with significant limitations. However, the combination of PET and magnetic resonance imaging (MRI) technologies is still the best option available today, as combined PET/MRI scans provide simultaneous data acquisition together with high quality anatomical information, sensitivity and lower radiation exposure for the patient. The coming years may represent a new era for the implementation of PET/MRI in clinical practice, but first, clinically efficient attenuation correction algorithms and research towards multimodal reagents and safety issues should be validated at the preclinical level. © Cambridge University Press, 2016.en
dc.language.isoenen
dc.sourceExpert Reviews in Molecular Medicineen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84964089835&doi=10.1017%2ferm.2016.5&partnerID=40&md5=12f181446743b5b51b18fe1e0237e47f
dc.subjectapolipoprotein Een
dc.subjectfluorodeoxyglucose f 18en
dc.subjectlow density lipoprotein receptoren
dc.subjectmetal nanoparticleen
dc.subjectradiopharmaceutical agenten
dc.subjectanimalen
dc.subjectatherosclerosisen
dc.subjectchemistryen
dc.subjectdeficiencyen
dc.subjectdevicesen
dc.subjectdiagnostic imagingen
dc.subjectdisease modelen
dc.subjectgeneticsen
dc.subjecthumanen
dc.subjectknockout mouseen
dc.subjectmagnetic resonance angiographyen
dc.subjectmetabolismen
dc.subjectmouseen
dc.subjectmultimodal imagingen
dc.subjectpathologyen
dc.subjectPlaque, Atheroscleroticen
dc.subjectpositron emission tomographyen
dc.subjectproceduresen
dc.subjectrabbits and haresen
dc.subjectradiographyen
dc.subjectAnimalsen
dc.subjectApolipoproteins Een
dc.subjectAtherosclerosisen
dc.subjectDisease Models, Animalen
dc.subjectFluorodeoxyglucose F18en
dc.subjectHumansen
dc.subjectMagnetic Resonance Angiographyen
dc.subjectMetal Nanoparticlesen
dc.subjectMiceen
dc.subjectMice, Knockouten
dc.subjectMultimodal Imagingen
dc.subjectPlaque, Atheroscleroticen
dc.subjectPositron-Emission Tomographyen
dc.subjectRabbitsen
dc.subjectRadiographyen
dc.subjectRadiopharmaceuticalsen
dc.subjectReceptors, LDLen
dc.subjectCambridge University Pressen
dc.titlePreclinical models of atherosclerosis. The future of hybrid PET/MR technology for the early detection of vulnerable plaqueen
dc.typeotheren


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής